Changing patients lives


AtmosR‘s mission is to develop innovative treatments for patients with rare, severe and sometimes fatal disorders of the central nervous system.

Originally created by patient families, AtmosR works daily in close proximity with the best world experts from academia and private laboratories, in order to best meet the needs expressed by patient communities.


Central Congenital Hypoventilation Syndrome (CCHS), also called the Ondine syndrome, is a rare genetic disorder of the autonomic nervous system, which main symptom is a lack of breathing at night and sometimes during the day.

There is no cure to this day. Patients are supported by vital mechanical ventilation and are constantly monitored by a third party as they do not experience the absence of ventilation.


AtmosR has developed a new series of orally available HSP90 inhibitors that can degrade protein aggregates in the brain.

As a chaperon protein, HSP90 is in charge of regulating protein folding in the cell, and genetic mutations in the cells can lead to deleterious protein aggregates in the brain. Inhibiting these HSP90 leads to the degradation of these misfolded proteins and their aggregates and therefore decrease neuronal toxicity and restore proper neuronal function. 

AtmosR has developed a new chemical series of HSP90 inhibitors that were specially designed for CNS indications as they retain high inhibitory activity, while being able to pass the blood brain barrier and access the brain, and having a manageable toxicity profile.



Our team is made up of multidisciplinary profiles covering all aspects of drug development in the field of rare diseases.

Xenia Proton de la Chapelle, CEO

Xenia has more than 20 years of experience in business management in various business sectors. 

After graduating from ESCP Europe (Paris Business School), Xenia held management positions in several large international companies (Ernst & Young, Elis, Generali) before creating her company Nascenza in the textile industry. Closely affected by a rare disease called CCHS, Xenia took over the presidency of the French CCHS Family Association in 2017 before setting up the AtmosR company. Xenia is also member of the Strategic Advisory Board of the MarMaRa Institute (Marseille Institute for Rare Diseases).

Nathan Beckouche

Nathan has worked in drug research and development for over 10 years.

Holder of a PhD in biology, physiology and physiopathology (UPMC,
Paris), he worked for 7 years in translational research at UPMC and then at the
University of San Francisco, California, before joining Alexion Pharmaceuticals as preclinical project manager.


Nicolas Pineau

Nicolas has worked for more than 20 years in the development of drugs, in particular on aspects related to valuation and Regulatory Affairs, in the specific field of orphan diseases. He holds a PhD in Cellular Biology and Pharmacology (Poitiers, France) and Executive MBA (University of Sherbrooke, Canada).

Nicolas began his career as regional manager then marketing manager at Genzyme, a subsidiary of Sanofi specializing in rare diseases. He then joined the French Rare Diseases Foundation at the time of its creation as Head of promotion of academic research projects, before co-founding the start-up OP2 Drugs specializing in cardiology.

Luc Berger

Luc has supported Healtech companies for more than 15 years in all their product development, market access and general business strategy issues.

With a double degree from the Ecole Centrale de Lyon and the Lyon School of  Management, he is a partner in the Alcimed firm in charge of the Health Business Unit.

Jean-Philippe Annereau

Jean-Philippe has worked for more than 25 years in drug development, in oncology and then in the field of rare diseases. Jean-Philippe holds a PhD in biochemistry (Polytechnique School, Paris);

He started his career as Head of the preclinical oncology research department at Pierre Fabre, before creating the French subsidiary of the rare diseases research laboratory of Alexion Pharmaceuticals within the Imagine Institute, which he directed during 5 years. In 2019, he founded the start-up Medetia specializing in ciliopathies.



AtmosR was born from the will of patients and patient families to find innovative treatments capable of transforming the daily lives of patients and their families. Patient centricity is part of AtmosR DNA.